Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE"
- Schöffski, Patrick
- Wozniak, Agnieszka
- Kasper, B
- Aamdal, S
- Leahy, MG
- Rutkowski, P
- Bauer, S
- Gelderblom, H
- Italiano, A
- Lindner, LH
- Hennig, I
- Strauss, S
- Zakotnik, B
- Anthoney, A
- Albiges, L
- Blay, J-Y
- Reichardt, P
- Sufliarsky, J
- van der Graaf, WTA
- Debiec-Rychter, Maria
- Sciot, Raf
- Van Cann, T
- Marréaud, S
- Raveloarivahy, T
- Collette, S
- Stacchiotti, S
Publication date
March 2018
DOI Publisher
Oxford University Press (OUP) Journal
Annals of OncologyAbstract
Alveolar soft part sarcoma(ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3(TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the tyrosine kinase inhibitor(TKI) crizotinib in patients with advanced or metastatic ASPS.status: publishe
Add to ORKG